Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Losartan vs Atenolol in Marfan Syndrome
NCT01145612Phase 3Unknown
- Start
- Oct 2008
- Primary completion
- Feb 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of losartan in Marfan syndrome (MFS) (2 arms). Primary endpoints: Progression of aortic dilation at 52 months and Safety of Losartan versus Atenolol at 52 months. Status: unknown.
02
Drugs
losartan
03
Conditions
Marfan syndrome (MFS)
Beyond the preview
Go deeper on NCT01145612.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01145612.